Quan Y, Liu JG, Cai YC, Zhang JR
[Changes of immune function in liver cancer patients after transcatheter arterial chemoembolizaton combined with interstitial therapy.] [JOURNAL ARTICLE]
Nan Fang Yi Ke Da Xue Xue Bao 2009 Nov 20; 29(11):2288-2290.
OBJECTIVE: To study the changes of immune function in patients with liver cancer after transcatheter arterial chemoembolizaton (TACE) combined with interstitial therapy.
METHODS: Forty patients with liver cancer were randomly divided into groups A and B to received TACE and TACE combined with percutaneous lipiodol and anti-cancer agent injection into the tumor. The T lymphocyte cell subsets in the peripheral blood before and one week after the operation were measured by flow cytometry, and the immunoglobulin contents determined by single radial immunodiffusion.
RESULTS: CD3, CD4, and CD4/8 levels increased significantly after the operation in both groups A and B (P<0.05). The postoperative CD3 and CD4 levels, but not that of CD8, differed significantly between the two groups (P<0.05). The operations also resulted in an increase in the contents of the immunoglobulins and complements in the two groups, but the changes were not significant in group A (P>0.05); in group B, significant increases occurred in the immunoglobulin and complement levels (P<0.05) with the exception of C3.
CONCLUSION: The combination of TACE and interstitial therapy with percutaneous intratumor injections of lipiodol and anti-cancer agents may better improve the cell-mediated immunity and humoral immune function of liver cancer patients.
More from this journal |
